Skip to content

Explore Grants

Recipient Purpose Term Amount
President and Fellows of Harvard College To analyze the impact of patient assistance programs on prescription drug pricing in the United States. 2018 - 2021 $147,197
George Mason University Foundation, Inc. To develop and disseminate policy options related to the negotiation of prescription drug prices by Medicare. 2018 $37,475
Memorial Sloan-Kettering Cancer Center To build a program that communicates evidence-based methodologies for drug pricing and payment. 2015 - 2019 $4,394,354
T1International To provide operating support for grantee's efforts to educate the public, patients, and key stakeholders about rising prescription drug prices. 2018 - 2020 $182,799
Henry J. Kaiser Family Foundation To examine trends in prescription drug prices and Medicare Part D formulary coverage and broadly disseminate the findings policy briefs, papers, and convenings. 2018 - 2020 $484,587
National Academy of Sciences To support an Institute of Medicine research project that will study patient access to effective and affordable therapies. 2016 - 2018 $749,161
Brigham & Women's Hospital, Inc. To support the Program On Regulation, Therapeutics, and Law, which will evaluate the impact of drug innovation incentive policies. 2016 - 2017 $742,905
The Alliance for Health Reform To educate health policy stakeholders and the public about the ways that prescription drug pricing impacts health care costs. 2016 - 2017 $156,494
Henry J. Kaiser Family Foundation To support Kaiser Health News in providing independent reporting on pharmaceutical drug development and pricing. 2016 - 2018 $1,060,500
National Academy of Sciences To host a workshop examining the role of the National Institutes of Health in prescription drug innovation in order increase patient access to products derived in part from federal research. 2018 - 2020 $254,960
Brigham & Women's Hospital, Inc. To evaluate the impact of Pharmacy Benefits Managers on prescription drug pricing. 2017 - 2018 $77,315
The Regents of the University of California, Berkeley To study the impact of extending reference pricing incentives to high-cost specialty pharmaceutical classes and physician-administered drugs. 2017 - 2021 $795,532
Henry J. Kaiser Family Foundation To support Kaiser Health News in providing independent reporting on pharmaceutical drug development and pricing. 2017 - 2018 $200,000
National Conference of State Legislatures To provide stakeholders with educational resources to support evidence-based decision making related to prescription drug pricing. 2017 - 2019 $264,427
Brigham & Women's Hospital, Inc. To support the Program On Regulation, Therapeutics, And Law. 2017 - 2020 $3,268,850
The Regents of the University of California, Hastings College of Law To analyze pharmaceutical industry behaviors and their impact on drug prices. 2017 - 2020 $652,120
Initiative for Medicines, Access, & Knowledge, Inc. To produce a report that will outline strategies to address pharmaceutical patents and pricing structures. 2016 $209,500
National Governors Association Center for Best Practices To convene national experts to discuss the rising cost of prescription drugs and potential policy solutions. 2017 - 2018 $200,000
Center for Health Policy Development To support a working group of state health policy experts and stakeholders to examine emerging strategies for addressing the high cost of prescription drugs. 2016 - 2017 $146,271
Trustees of Boston University To analyze the relationship between prices, regulations, and investments in prescription drugs. 2018 - 2020 $195,528
Initiative for Medicines, Access, & Knowledge, Inc. To support efforts to provide patients with affordable access to life-saving medications and improve public health. 2017 - 2019 $3,958,828
Oregon Health & Science University To support efforts to improve the Medicaid drug purchasing process through research and design of value-based payment models. 2016 - 2017 $1,582,837
Center for Health Policy Development To support the launch of the Center for Prescription Drug Price Action. 2017 - 2019 $2,021,350
Waxman Consulting, Inc. To provide nonpartisan information and technical support to key stakeholders regarding prescription drug policy and publicly disseminate educational resources. 2018 - 2019 $503,352
Arnold A decorative icon